Rigel enrols first patients in phase 2 Covid-19 trial of fostamatinib

This article was originally published here

The National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), along with Inova Health System, has sponsored the trial. Fostamatinib, which is sold

The post Rigel enrols first patients in phase 2 Covid-19 trial of fostamatinib appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply